Abstract 320P
Background
Ovarian cancer is 3rd most common malignancy in Indian women and 8th common cause of cancer related death in India. The aim for this study was to evaluate clinicopathological factors, patterns of treatment, progression free survival (PFS) and overall survival (OS) in Indian patients with advanced ovarian cancer.
Methods
This is a retrospective analysis of patients with stage III-IV ovarian cancer treated at HCG Cancer Center, Ahmedabad from June 2018- March 2023. Patients were identified using the institutional tumor registry and medical records and data was collected.
Results
Out of total 94 patients identified; 79 patients were eligible for further analysis. Median age was 55 years (range 29 to 76 years). 62 (78%) patients had stage III (IIIA-5,IIIB-3, IIIc-44) & 17 (22%) had stage IV (IVA-10, IVB-7). Most common histology was high grade serous carcinoma in 76 (96%) patients. Majority of patients received neoadjuvant chemotherapy followed by interim cytoreductive surgery (CRS), [61 patients (78%)] whereas 18 patients (22 %) underwent upfront surgery. Median duration of neoadjuvant chemotherapy was 3 months. 21 (26.57%) patients were treated with hyperthermic intraperitoneal chemotherapy (HIPEC). 60 patients (76%) received maintenance therapy [43 patients bevacizumab, 10 patients PARP (poly ADP ribose polymerase) inhibitor and 6 patients received both]. 33 patients (41%) developed recurrence among which 32 received further chemotherapy. In recurrent setting, patients received a median 3 lines of systemic therapy (range 0-5). Genetic testing was offered to all patients at the time of diagnosis, but only 36 (45%) patients opted for it. BRCA1 mutation was detected in 8 patients (22.2%), BRCA2 mutation in 4 (11%). Median follow up was 17 months. Median PFS was 20 months with 95% CI (16-22) & Median OS was not reached, 5-year OS was 32.1%.
Conclusions
Median PFS and OS in advanced ovarian cancer at our institute is comparable to global standards. With the availability of biosimilars and genetic testing, more patients are able to access maintenance therapies. Hopefully more patients can access standard of care therapies which will help close the gap between less developed and developed countries in terms of long term outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
397P - Comparison between Y-site co-infusion versus standard dexamethasone for preventing hypersensitivity reactions from oxaliplatin administration: A randomized controlled trial
Presenter: jarearnjit Phavirunsiri
Session: Poster Display
Resources:
Abstract
398P - Evaluation of the effectiveness of denosumab therapy giant cell tumor of the pelvis
Presenter: Abbos Nurjabov
Session: Poster Display
Resources:
Abstract
399P - Long-term outcomes of patients with gastric cancer who received the best supportive care without any anticancer treatment
Presenter: Yohei Arihara
Session: Poster Display
Resources:
Abstract
401TiP - Oral opioid vs intravenous patient-controlled analgesia (PCA) with hydromorphone bolus-only or continuous infusion to maintain analgesia for severe cancer pain: A randomized phase III trial
Presenter: Cheng Huang
Session: Poster Display
Resources:
Abstract
407P - K-TrackTM: A streamlined personalized assay to detect molecular residual disease in solid tumors
Presenter: Nam Vo
Session: Poster Display
Resources:
Abstract
408P - Increased EGFR and MET expression and corresponding tumor microenvironment (TME) change in hepatocellular carcinoma (HCC) tissues after sorafenib (Sora) treatment
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
410P - Systematic evaluation of cell-free DNA fragmentation patterns for cancer diagnosis and enhanced cancer detection through integration of multiple fragmentations
Presenter: Xiangy-Yu Meng
Session: Poster Display
Resources:
Abstract
412P - Multiplex digital spatial profiling (DSP) of protein reveals distinct immune and molecular phenotypes in hepatocellular carcinoma
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
413P - Clinical utility of advanced features provided by circulating tumor DNA-based comprehensive genomic profiling
Presenter: Young-gon Kim
Session: Poster Display
Resources:
Abstract
414P - Landscape of ERBB2 mutations in advanced cancers (AC) using circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and Middle East (AME)
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract